GLP-1 therapies are rapidly transforming the conversation around chronic disease management, obesity and employee health. As their role continues to evolve, multinational employers are facing important questions around access, affordability and long-term health outcomes.
Join Dr Leena Johns, our Chief Health and Wellness Officer, at IEBA’s UK meeting on 18 November, where she will share key insights from the MAXIS 2026 whitepaper, drawing on medical claims data covering more than 7.9 million insured lives worldwide.
Going beyond the headlines, the whitepaper explores emerging claims trends, why GLP-1s should be viewed as more than weight-loss drugs, and the considerations employers should take into account when developing their approach to these therapies.
The session will take place at Marsh’s office in Tower Place from 4.30pm-6pm, followed by networking drinks and finger food for delegates attending in person.
For more information, contact [email protected].